Teva Pharmaceutical Industries Ltd
$
15.14
0.14 (0.93%)
| Volume: | 7,353,362 | Avg Vol (1m): | 10,803,617 |
| Market Cap $: | 16.74 Bil | Enterprise Value $: | 44.96 Bil |
| P/E (TTM): | 0.00 | P/B: | 1.07 |
| Earnings Power Value | 26.74 |
| Net Current Asset Value | -31.18 |
| Tangible Book | -23.46 |
| Projected FCF | 41.57 |
| Median P/S Value | 40.26 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 4/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 0.06 | ||
| Equity-to-Asset | 0.24 | ||
| Debt-to-Equity | 1.97 | ||
| Debt-to-EBITDA | 174.19 | ||
| Interest Coverage | 3.36 | ||
| Piotroski F-Score | 5 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 0.28 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.60 |
Not Manipulator
Manipulator
| |
Profitability & Growth : 5/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 16.38 | ||
| Net Margin % | -11.40 | ||
| ROE % | -13.89 | ||
| ROA % | -3.23 | ||
| ROC (Joel Greenblatt) % | -23.01 | ||
| 3-Year Total Revenue Growth Rate | -1.40 | ||
| 3-Year Total EBITDA Growth Rate | -65.20 | N/A |
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NYSE:TEVA
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Drug Manufacturers » Drug Manufacturers - Specialty & Generic   NAICS : 325412 |
| Compare | SHSE:600518 TSE:4507 NSE:SUNPHARMA SZSE:000538 TSE:4523 SHSE:600196 NAS:MYL XPAR:IPN OCSE:LUN NYSE:PRGO TSE:4508 SZSE:000963 XSWX:VIFN SZSE:300122 JSE:APN SHSE:600332 HKSE:03320 SHSE:600085 TSE:4581 SHSE:600535 |
| Traded in other countries | TEV.Germany TEVAN.Mexico |
| Address | 5 Basel Street, Petach Tikva, ISR, 4951033 |
| Headquartered in Israel, Teva Pharmaceutical is the world's largest generic pharmaceutical manufacturer. The company also develops and sells branded pharmaceuticals in central nervous system, oncology, respiratory, and women's health categories. After acquiring Allergan's generics business, Teva's generic sales should be over 60% of total revenue, with branded drug and international over-the-counter revenue making up the balance of sales. Copaxone makes up about half of Teva's branded drug segment, with about $4 billion in sales for 2015. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| Forward PE Ratio | 6.37 | N/A | |
| PB Ratio | 1.07 | ||
| PS Ratio | 0.86 | ||
| Price-to-Free-Cash-Flow | 8.73 | ||
| Price-to-Operating-Cash-Flow | 6.41 | ||
| EV-to-EBIT | -26.41 | ||
| EV-to-EBITDA | 266.63 | ||
| EV-to-Revenue | 2.36 | ||
| Shiller PE Ratio | 136.31 | ||
| Current Ratio | 0.96 | ||
| Quick Ratio | 0.63 | ||
| Days Inventory | 170.12 | ||
| Days Sales Outstanding | 112.71 | ||
| Days Payable | 64.06 |
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Dividend Growth Rate (Per Share) | -100.00 | N/A | |
| 3-Year Share Buyback Rate | -3.90 |
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Projected-FCF | 0.36 | ||
| Price-to-Median-PS-Value | 0.38 | ||
| Earnings Yield (Joel Greenblatt) % | -3.80 | ||
| Forward Rate of Return (Yacktman) % | 21.93 |
More Statistics
| Revenue (TTM) (Mil) $ | 18,854 |
| EPS (TTM) $ | -2.33 |
| Beta | 2.09 |
| Volatility % | 53.88 |
| 52-Week Range $ | 14.04 - 25.96 |
| Shares Outstanding (Mil) | 1,091.6 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 5 |
| Positive ROA | N |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | N |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | Y |